The expert council of the Japanese Ministry of Health has approved two regenerative medicine drugs based on induced pluripotent stem cells (iPSCs) — a cure for Parkinson’s disease and heart failure. If the health minister approves the experts’ decision, Japan will become the first country in the world to allow the commercial sale of such products — almost 20 years after the discovery of the technology itself.

Japan’s health ministry said on Thursday a panel of specialists had endorsed Sumitomo Pharma’s iPS cell-derived treatment for Parkinson’s disease, paving the way for the world’s first medical products based on the technology.